A new clinical trial investigating the effects of a text-based intervention on health-related quality of life in patients with pulmonary arterial hypertension (PAH) is now open. 

The trial sponsored by Vanderbilt University Medical Center in Nashville, Tennessee, will have 2 arms. An estimated 100 participants will be randomly assigned to each arm.

Those in the first arm will receive 3 text messages a day, which are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue, for 24 weeks. Those in the second arm will receive their usual routine medical care. 


Continue Reading

The study will assess the effects of the program on health-related quality of life using the PAH-specific emPHasis-10 questionnaire. It will also measure patients’ exercise capacity using a supervised home-based 6-minute walk distance test and clinical worsening 1 year later, measured using the composite of PAH therapy escalation and the number of patients who are hospitalized or died because of PAH.

Read more about PAH

The trial is not yet recruiting participants. It is estimated to be initiated on September 1, 2022, and run through August 1, 2027, at Vanderbilt. 

Patients aged at least 18 years with a diagnosis of idiopathic, heritable, or associated PAH or PAH caused by congenital heart disease, WHO functional class I to III are eligible to participate in the trial. Participants must also have a forced vital capacity of more than 65% predicted with no or minimal interstitial lung disease and be on a stable PAH-specific medication regimen for 3 months before enrollment. Patients who are pregnant, have a condition that is limiting their activity, or have functional class IV heart failure are not eligible. 

PAH impairs health-related quality of life and reduces exercise capacity. Physical activity has been shown to increase patients’ health-related quality of life and provide benefits that exceed the effects of medication.

Reference

The mobile health intervention in pulmonary arterial hypertension (MOVE PAH) study (MOVE PAH)). US National Library of Medicine. Last updated July 19, 2022. Accessed July 21. 2022.